Skip to main content

Table 3 Subgroup analysis of the meta-analysis for PFS

From: Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis

Subgroup No. of studies No. of patients Pooled HR 95% CI P Heterogeneity test Statistical method
I2 P
Analysis of survival
 Multivariate 9 [1, 7, 29, 35, 41, 44,45,46,47] 2487 1.30 1.14–1.47 < 0.001 37.1% 0.080 Fixed
 Univariate 5 [11, 22, 28, 34, 36] 2660 1.19 1.01–1.40 0.036 0.0% 0.441 Fixed
Cut-off value
 ≤ 1.0 5 [1, 7, 41, 45, 46] 1187 1.55 1.32–1.82 < 0.001 0.0% 0.617 Fixed
 > 1.0 9 [11, 22, 28, 29, 34,35,36, 44, 47] 3960 1.11 0.99–1.24 0.053 0.0% 0.643 Fixed
Disease site
 Nasopharyngeal cancer 3 [22, 29, 44] 2074 1.31 1.12–1.53 0.001 0.0% 0.444 Fixed
 Breast cancer 2 [1, 45] 482 1.76 1.42–2.20 < 0.001 0.0% 0.820 Fixed
 Renal cancer 2 [11, 41] 332 1.15 0.84–1.59 0.36 0.0% 0.690 Fixed
Disease stage
 Non metastatic 6 [7, 28, 29, 34, 44, 46] 2814 1.34 1.14–1.56 < 0.001 0.0% 0.612 Fixed
 Metastatic 3 [1, 41, 45] 856 1.54 1.30–1.84 < 0.001 15.2% 0.316 Fixed
 Mixed 5 [11, 22, 35, 36, 47] 1477 1.10 0.97–1.24 0.138 0.0% 0.528 Fixed
Region
 Asian(China, Korea, Japan) 7 [22, 28, 29, 34, 35, 44, 47] 3408 1.20 1.07–1.34 0.002 20.2% 0.257 Fixed
 Non Asian(America, France, Italy) 7 [1, 7, 11, 36, 41, 45, 46] 1739 1.37 1.20–1.55 < 0.001 31.6% 0.176 Fixed